Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer (POLEM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03827044
Recruitment Status : Recruiting
First Posted : February 1, 2019
Last Update Posted : February 5, 2019
Sponsor:
Collaborators:
University of Surrey
University of Oxford
Merck KGaA, Darmstadt, Germany
Information provided by (Responsible Party):
Royal Marsden NHS Foundation Trust

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 2024
Estimated Study Completion Date : July 2028